National Reference Laboratory for Plague, Tularemia and Q Fever, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Akanlu, KabudarAhang, Hamadan, Iran.
Department of Epidemiology and Biostatics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Curr Microbiol. 2024 Apr 2;81(5):126. doi: 10.1007/s00284-024-03658-0.
Francisella tularensis is a facultative intracellular bacterial pathogen that affects both humans and animals. It was developed into a biological warfare weapon as a result. In this article, the current status of tularemia vaccine development is presented. A live-attenuated vaccine that was designed over 50 years ago using the less virulent F. tularensis subspecies holarctica is the only prophylactic currently available, but it has not been approved for use in humans or animals. Other promising live, killed, and subunit vaccine candidates have recently been developed and tested in animal models. This study will investigate some possible vaccines and the challenges they face during development.
土拉弗朗西斯菌是一种兼性细胞内细菌病原体,既影响人类也影响动物。它因此被开发成一种生物战武器。本文介绍了土拉弗朗西斯菌疫苗开发的现状。一种 50 多年前使用毒力较弱的土拉弗朗西斯菌亚种 holarctica 设计的减毒活疫苗是目前唯一可用的预防性疫苗,但尚未获准在人类或动物中使用。其他有前途的活疫苗、死疫苗和亚单位疫苗候选物最近已在动物模型中开发和测试。本研究将探讨一些可能的疫苗及其在开发过程中面临的挑战。